Skip to main content
SpringerLink
Log in

PET/CT for HL Staging

  • Chapter
  • First Online:
PET Scan in Hodgkin Lymphoma

  • 894 Accesses

Abstract

Accurate baseline staging of Hodgkin lymphoma (HL) is crucial for prognostication and guides important treatment decisions. This remains true in the era of highly effective combined modality treatments and intensive multi-agent chemotherapy regimens that lead to cure in the vast majority of HL patients irrespective of disease stage [1, 2]. In the early 1970s the Committee on Hodgkin’s Disease Staging Classification convened in Ann Arbor, Michigan, and this resulted in the first staging classification for HL which was named after the city [3]. The Ann Arbor staging classification became the widely accepted classification for disease staging in HL and enabled comparison of studies by different investigators. The main clinical purpose of the Ann Arbor Classification was to accurately identify patients with limited-stage HL who could be treated with a curative intent with radiotherapy alone. Accurate staging was pursued through rigorous procedures, which included both a clinical and a pathological staging workup. Clinical stage was determined from physical examination, symptom assessment, lymphangiograms, and radiograms, some of which are still elements in modern HL staging. Pathological stage was derived from the results of invasive staging procedures including diagnostic laparotomy and iliac crest bone marrow biopsy (BMB). The risk of serious complications and discomfort related to invasive procedures were tolerated at that time as no good alternatives for evaluation of deep lymph node regions and organs were available. The introduction of computed tomography (CT) enabled noninvasive assessment of deep lymph node regions/organs and changed the staging of HL fundamentally. The committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease met in the Cotswolds (UK) and the report generated by the committee recommended CT of the thorax and abdomen in the routine staging workup of HL. Invasive staging procedures with the exception of iliac crest bone marrow biopsy were no longer considered necessary (Cotswold modifications of the Ann Arbor Classification) [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Engert A, Diehl V, Franklin J, Lohri A, Dorken B, Ludwig WD, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–54.

    Article  PubMed  Google Scholar 

  2. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363(7):640–52.

    Article  CAS  PubMed  Google Scholar 

  3. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971;31(11):1860–1.

    CAS  PubMed  Google Scholar 

  4. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–6.

    CAS  PubMed  Google Scholar 

  5. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25–30.

    Article  PubMed  Google Scholar 

  6. Bangerter M, Moog F, Buchmann I, Kotzerke J, Griesshammer M, Hafner M, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol. 1998;9(10):1117–22.

    Article  CAS  PubMed  Google Scholar 

  7. Partridge S, Timothy A, O’Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin’s disease: influence on patient management in a single institution. Ann Oncol. 2000;11(10):1273–9.

    Article  CAS  PubMed  Google Scholar 

  8. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica. 2001;86(3):266–73.

    CAS  PubMed  Google Scholar 

  9. Weihrauch MR, Re D, Bischoff S, Dietlein M, Scheidhauer K, Krug B, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin’s disease. Ann Hematol. 2002;81(1):20–5.

    Article  CAS  PubMed  Google Scholar 

  10. Cerci JJ, Trindade E, Buccheri V, Fanti S, Coutinho AMN, Zanoni L, et al. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions. Clin Lymphoma Myeloma Leuk. 2011;11(4):314–20.

    Article  PubMed  Google Scholar 

  11. Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica. 2006;91(4):482–9.

    PubMed  Google Scholar 

  12. Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol. 2006;24(3):146–50.

    Article  CAS  PubMed  Google Scholar 

  13. Bednaruk-Młyński E, Pieńkowska J, Skórzak A, Małkowski B, Kulikowski W, Subocz E, et al. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. Leuk Lymphoma. 2014;56(2):377–82.

    Article  PubMed  Google Scholar 

  14. El Galaly TC, Hutchings M, Mylam KJ, Brown Pde N, Bukh A, Johnsen HE, et al. Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. Leuk Lymphoma. 2014;55(10):2349–55.

    Article  PubMed  Google Scholar 

  15. Grellier J, Vercellino L, Leblanc T, Merlet P, Thieblemont C, Weinmann P, et al. Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2023–30.

    Article  PubMed  Google Scholar 

  16. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431–9.

    Article  PubMed  Google Scholar 

  17. Hutchings M. How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma? ASH Educ Program Book. 2012;2012(1):322–7.

    Google Scholar 

  18. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79(3):270–7.

    Article  PubMed  Google Scholar 

  19. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–58.

    Article  PubMed  Google Scholar 

  20. Chiaravalloti A, Danieli R, Caracciolo CR, Travascio L, Cantonetti M, Gallamini A, et al. Initial staging of Hodgkin’s disease: role of contrast-enhanced 18F FDG PET/CT. Medicine. 2014;93(8), e50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KDM, von Schulthess GK, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging – do we need contrast-enhanced CT? Radiology. 2004;232(3):823–9.

    Article  PubMed  Google Scholar 

  22. Chalaye J, Luciani A, Enache C, Beaussart P, Lhermite C, Evangelista E, et al. Clinical impact of contrast-enhanced computed tomography combined with low-dose 18F-fluorodeoxyglucose positron emission tomography/computed tomography on routine lymphoma patient management. Leuk Lymphoma. 2014;55(12):2887–92.

    Article  CAS  PubMed  Google Scholar 

  23. Vriens D, Visser E, de Geus-Oei L-F, Oyen W. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging. 2010;37(7):1408–25.

    Article  PubMed  Google Scholar 

  24. Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Højgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging. 2005;32(10):1167–75.

    Article  CAS  PubMed  Google Scholar 

  25. El Galaly TC, d’Amore F, Mylam KJ, Nully Brown P, Bøgsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508–14.

    Article  PubMed  Google Scholar 

  26. Weiler-Sagie M, Kagna O, Dann E, Ben Barak A, Israel O. Characterizing bone marrow involvement in Hodgkin’s lymphoma by FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2014;41(6):1133–40.

    Article  PubMed  Google Scholar 

  27. Purz S, Mauz-Körholz C, Körholz D, Hasenclever D, Krausse A, Sorge I, et al. [18F]fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin’s lymphoma. J Clin Oncol. 2011;29(26):3523–8.

    Article  PubMed  Google Scholar 

  28. Chen-Liang TH, Martin-Santos T, Jerez A, Senent L, Orero MT, Remigia MJ, et al. The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma. accuracy in a multicenter series of 372 patients. Am J Hematol. 2015;90(8):686–90.

    Article  CAS  PubMed  Google Scholar 

  29. Howell SJ, Grey M, Chang J, Morgenstern GR, Cowan RA, Deakin DP, et al. The value of bone marrow examination in the staging of Hodgkin’s lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol. 2002;119(2):408–11.

    Article  PubMed  Google Scholar 

  30. Levis A, Pietrasanta D, Godio L, Vitolo U, Ciravegna G, Di Vito F, et al. A large-scale study of bone marrow involvement in patients with Hodgkin’s lymphoma. Clin Lymphoma. 2004;5(1):50–5.

    Article  PubMed  Google Scholar 

  31. BRUNNING RD, BLOOMFIELD CD, McKENNA RW, PETERSON L. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med. 1975;82(3):365–6.

    Article  CAS  PubMed  Google Scholar 

  32. Adams H, Kwee T, Fijnheer R, Dubois S, Nievelstein R, de Klerk J. Bone marrow FDG-PET/CT in Hodgkin lymphoma revisited: do imaging and pathology match? Ann Nucl Med. 2015;29(2):132–7.

    Article  PubMed  Google Scholar 

  33. Adams HJA, Kwee TC, de Keizer B, Fijnheer R, de Klerk JMH, Littooij AS, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol. 2014;25(5):921–7.

    Article  CAS  PubMed  Google Scholar 

  34. Adams HJA, Kwee TC, Fijnheer R, Dubois SV, Nievelstein RAJ, de Klerk JMH. Diffusely increased bone marrow FDG uptake in recently untreated lymphoma: incidence and relevance. Eur J Haematol. 2015;95(1):83–9.

    Article  CAS  PubMed  Google Scholar 

  35. Chiang SB, Rebenstock A, Guan L, Alavi A, Zhuang H. Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging. Clin Nucl Med. 2003;28(8):674–6.

    PubMed  Google Scholar 

  36. Zwarthoud C, Ouvier M, Borra A, Bergesio F, Chauvie S, Biggi A, et al. Patterns of PET/CT-assessed bone-marrow involvement in newly diagnosed Hodgkin lymphoma; a detailed review of 150 ABVD treated patients. Leuk Lymphoma. 2015;56:1233. Ref Type: Abstract.

    Article  Google Scholar 

  37. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.

    Article  PubMed  Google Scholar 

  38. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44(9):1426–31.

    CAS  PubMed  Google Scholar 

  39. Sandherr M, von Schilling C, Link T, Stock K, von Bubnoff N, Peschel C, et al. Pitfalls in imaging Hodgkin’s disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol. 2001;12(5):719–22.

    Article  CAS  PubMed  Google Scholar 

  40. Martiat P, Ferrant A, Labar D, Cogneau M, Bol A, Michel C, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin’s lymphoma using positron emission tomography. J Nucl Med. 1988;29(10):1633–7.

    CAS  PubMed  Google Scholar 

  41. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39(10):1757–62.

    CAS  PubMed  Google Scholar 

  42. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4(11):1334–6.

    Article  CAS  PubMed  Google Scholar 

  43. Buchmann I, Neumaier B, Schreckenberger M, Reske S. [18F]3′-deoxy-3′-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study. Cancer Biother Radiopharm. 2004;19(4):436–42.

    CAS  PubMed  Google Scholar 

  44. Buck AK, Bommer M, Stilgenbauer S, Juweid M, Glatting G, Schirrmeister H, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66(22):11055–61.

    Article  CAS  PubMed  Google Scholar 

  45. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma. 2007;48(4):746–53.

    Article  PubMed  Google Scholar 

  46. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34(11):1775–82.

    Article  CAS  PubMed  Google Scholar 

  47. Herrmann K, Buck AK, Schuster T, Rudelius M, Wester HJ, Graf N, et al. A pilot study to evaluate 3′-deoxy-3′-18F-fluorothymidine PET for initial and early response imaging in mantle cell lymphoma. J Nucl Med. 2011;52(12):1898–902.

    Article  CAS  PubMed  Google Scholar 

  48. Herrmann K, Buck AK, Schuster T, Junger A, Wieder H, Graf N, et al. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment. J Nucl Med. 2011;52(5):690–6.

    Article  PubMed  Google Scholar 

  49. Graf N, Herrmann K, den Hollander J, Fend F, Schuster T, Wester HJ, et al. Imaging proliferation to monitor early response of lymphoma to cytotoxic treatment. Mol Imaging Biol. 2008;10(6):349–55.

    Article  PubMed  Google Scholar 

  50. Hoffman RM. Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta. 1984;738(1-2):49–87.

    CAS  PubMed  Google Scholar 

  51. Stern PH, Wallace CD, Hoffman RM. Altered methionine metabolism occurs in all members of a set of diverse human tumor cell lines. J Cell Physiol. 1984;119(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  52. Wheatley DN. On the problem of linear incorporation of amino acids into cell protein. Experientia. 1982;38(7):818–20.

    Article  CAS  PubMed  Google Scholar 

  53. Leskinen-Kallio S, Ruotsalainen U, Nagren K, Teras M, Joensuu H. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin’s lymphoma: a PET study. J Nucl Med. 1991;32(6):1211–8.

    CAS  PubMed  Google Scholar 

  54. Nuutinen J, Leskinen S, Lindholm P, Soderstrom KO, Nagren K, Huhtala S, et al. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas. Eur J Nucl Med. 1998;25(7):729–35.

    Article  CAS  PubMed  Google Scholar 

  55. Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 suppl 3:iii70–5.

    Article  PubMed  Google Scholar 

  56. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94.

    Google Scholar 

  57. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.

    Article  CAS  PubMed  Google Scholar 

  58. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–65.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark

    Martin Hutchings

  2. Department of Clinical Physiology and Nuclear Medicine – PET and Cyclotron Unit, Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen, Denmark

    Annika Loft

  3. Department of Hematology, Aalborg University Hospital, Moelleparkvej 4, DK-9100, Aalborg, Denmark

    Tarec Christoffer El-Galaly

Authors
  1. Martin Hutchings
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annika Loft
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tarec Christoffer El-Galaly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Hutchings .

Editor information

Editors and Affiliations

  1. Research, Innovation and Statistics, A. Lacassagne Cancer Center, Nice, France

    Andrea Gallamini

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hutchings, M., Loft, A., El-Galaly, T.C. (2016). PET/CT for HL Staging. In: Gallamini, A. (eds) PET Scan in Hodgkin Lymphoma. Springer, Cham. https://doi.org/10.1007/978-3-319-31797-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-31797-7_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-31795-3

  • Online ISBN: 978-3-319-31797-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation